Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
$11.41
+0.7%
$10.43
$7.80
$28.09
$618.20MN/A308,532 shs368,592 shs
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
$14.42
+3.3%
$13.95
$9.12
$72.37
$566.99M1.33453,048 shs460,243 shs
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
$2.60
-5.5%
$2.42
$1.66
$9.95
$700.31M0.281.74 million shs1.05 million shs
Nkarta, Inc. stock logo
NKTX
Nkarta
$2.20
-0.5%
$1.92
$1.31
$6.63
$156.96M0.72594,389 shs827,367 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
+0.71%+11.86%+11.53%-21.15%+1,140,999,900.00%
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
+3.30%+7.93%+1.19%+2.49%-66.75%
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
-5.45%+28.08%+0.39%+23.81%-68.37%
Nkarta, Inc. stock logo
NKTX
Nkarta
-0.45%+9.45%+20.88%+26.44%-57.12%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
1.9976 of 5 stars
3.50.00.00.02.00.80.6
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
2.4494 of 5 stars
3.32.00.00.01.53.30.6
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
3.7033 of 5 stars
3.13.00.04.41.10.80.6
Nkarta, Inc. stock logo
NKTX
Nkarta
2.0589 of 5 stars
3.50.00.00.03.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
3.00
Buy$31.86179.22% Upside
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
2.50
Moderate Buy$30.00108.04% Upside
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
2.25
Hold$5.75121.15% Upside
Nkarta, Inc. stock logo
NKTX
Nkarta
3.00
Buy$13.60518.18% Upside

Current Analyst Ratings Breakdown

Latest NKTX, MRVI, KROS, and BCAX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/14/2025
Nkarta, Inc. stock logo
NKTX
Nkarta
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$14.00 ➝ $12.00
8/13/2025
Nkarta, Inc. stock logo
NKTX
Nkarta
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
8/12/2025
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$30.00
8/12/2025
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$7.00 ➝ $5.00
8/8/2025
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$25.00 ➝ $20.00
6/10/2025
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$32.00 ➝ $18.00
6/10/2025
Nkarta, Inc. stock logo
NKTX
Nkarta
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$16.00 ➝ $14.00
5/30/2025
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$15.00
5/23/2025
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderweight ➝ Equal Weight$8.00
5/23/2025
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$30.00
5/16/2025
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$44.00 ➝ $41.00
(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/AN/AN/AN/A$7.98 per shareN/A
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
$3.55M165.00N/AN/A$17.40 per share0.83
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
$259.18M2.55$0.58 per share4.45$1.84 per share1.41
Nkarta, Inc. stock logo
NKTX
Nkarta
N/AN/AN/AN/A$5.04 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
-$68M-$3.170.00N/AN/AN/A-21.67%-20.89%N/A
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
-$187.35M$0.3145.03N/A1.718.06%2.96%2.74%N/A
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
-$144.85M-$1.360.00N/AN/A-90.03%-17.60%-9.30%N/A
Nkarta, Inc. stock logo
NKTX
Nkarta
-$108.79M-$1.480.00N/AN/AN/A-27.74%-22.38%N/A

Latest NKTX, MRVI, KROS, and BCAX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
-$0.54-$0.50+$0.04-$0.50N/AN/A
8/12/2025Q2 2025
Nkarta, Inc. stock logo
NKTX
Nkarta
-$0.37-$0.31+$0.06-$0.31N/AN/A
8/6/2025Q2 2025
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
-$1.14-$0.76+$0.38-$0.76$3.83 million$0.02 million
5/14/2025Q1 2025
Nkarta, Inc. stock logo
NKTX
Nkarta
-$0.44-$0.43+$0.01-$0.43N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/AN/AN/AN/AN/A
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
N/AN/AN/AN/AN/A
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
N/AN/AN/AN/AN/A
Nkarta, Inc. stock logo
NKTX
Nkarta
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/A
25.80
24.62
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
N/A
21.11
21.11
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
0.68
5.16
5.17
Nkarta, Inc. stock logo
NKTX
Nkarta
N/A
15.67
14.48

Institutional Ownership

CompanyInstitutional Ownership
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/A
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
71.56%
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
50.25%
Nkarta, Inc. stock logo
NKTX
Nkarta
80.54%

Insider Ownership

CompanyInsider Ownership
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
15.50%
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
20.60%
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
2.11%
Nkarta, Inc. stock logo
NKTX
Nkarta
8.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
3254.56 million46.08 millionN/A
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
10040.62 million32.25 millionOptionable
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
610254.66 million249.29 millionOptionable
Nkarta, Inc. stock logo
NKTX
Nkarta
14071.03 million65.00 millionOptionable

Recent News About These Companies

Nkarta, Inc. Reports Q2 2025 Financial Results
Nkarta (NKTX) Projected to Post Earnings on Tuesday
Will Nkarta (NASDAQ:NKTX) Spend Its Cash Wisely?
Nkarta, Inc. (NKTX) - Yahoo Finance
William Blair Downgrades Nkarta (NKTX)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bicara Therapeutics stock logo

Bicara Therapeutics NASDAQ:BCAX

$11.41 +0.08 (+0.71%)
Closing price 08/14/2025 04:00 PM Eastern
Extended Trading
$11.42 +0.02 (+0.13%)
As of 08/14/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Keros Therapeutics stock logo

Keros Therapeutics NASDAQ:KROS

$14.42 +0.46 (+3.30%)
Closing price 08/14/2025 04:00 PM Eastern
Extended Trading
$14.29 -0.13 (-0.93%)
As of 08/14/2025 06:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Maravai LifeSciences stock logo

Maravai LifeSciences NASDAQ:MRVI

$2.60 -0.15 (-5.45%)
Closing price 08/14/2025 04:00 PM Eastern
Extended Trading
$2.60 +0.00 (+0.19%)
As of 08/14/2025 04:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

Nkarta stock logo

Nkarta NASDAQ:NKTX

$2.20 -0.01 (-0.45%)
Closing price 08/14/2025 04:00 PM Eastern
Extended Trading
$2.20 0.00 (0.00%)
As of 08/14/2025 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.